Jose Pablo Brenes

Oncología Médica

[Elvina Almuradova @Dr_ElvinaA]

As a medical oncologist, this is one of the most disturbing breast cancer papers I have read recently.
Despite all advances in screening, awareness, and treatment, the incidence of de novo Stage IV breast cancer continues to rise. Even younger patients and men showed increasing rates!
@Larvol @OncoDailyIO @OncoAlert #breastcancer #cancer @PTarantinoMD

[Annals of Oncology @Annals_Oncology]

🔥New @myESMO mCRC guidelines!
👉Precision oncology at the core
👉Clear biomarker hierarchy
👉Locoregional strategies in limited disease
👉Patient characteristics & preferences central
Read more:
https://t.co/UEwZ6BqDp8

[Paolo Tarantino @PTarantinoMD]

Combining trained detection dogs indications with a Bayesian framework incorporating historical dog performance and participants features yielded 90.8% sensitivity & 91.3% specificity for multicancer detection from breath. Truly the human’s best friend! 🐶 https://t.co/YoSBWCGVWO

[Oncology Brothers @OncBrothers]

Our patients are vulnerable and some buy into this. It’s our job to continue discussions around misinformation like this!

He uses breast cancer as an example… so to build up on it, biopsy is essential for us to appreciate the TYPE of breast cancer so that we can recommend the right treatment (endocrine therapy, anti-her2 agents, or perhaps chemo-IO). Also, it can help adequately stage if we are worried about LN involvement so that we don’t UNDER or OVER TREAT!

#OncTwitter #MedTwitter @JaniceTNBCmets @AMJohnston1315 @Dr_RShatsky @drteplinsky @ThanksCancer

[Dr Rishabh Jain @DrRishabhOnco]

TNBC is no longer a chemo disease.

This 1 algorithm shows the shift:
👉 ADCs + biomarkers are now driving frontline decisions.

🧬 Metastatic TNBC - how to think today

PD-L1 ≥10
• Pembro + chemo
• OR Pembro + SG

PD-L1 <10
• SG or Dato-DXd now competing with chemo

BRCA-mut
• PARP inhibitors

HER2-low
• T-DXd option

Later lines
• ADC sequencing
• Biomarker-directed therapy

🧠 Paradigm shift

❌ Before: one-size chemo
✅ Now: IO + ADCs + PARPi + precision oncology

⚠️ What matters next

Not just “which drug”
👉 but “what sequence”

Topo-1 ADCs → real cross-resistance concern

🎯 Takeaway

Advanced TNBC has entered the ADC era.

Smart sequencing will define outcomes. 🔖

📖 Full paper in comment ⬇️

#OncoTwitter #MedTwitter #TNBC #BreastCancer @OncoAlert @myesmo @esmo_open @JCOPO_ASCO

[Yakup Ergün @dr_yakupergun]

The first rule of medicine is: first, do no harm!

In oncology, that does not mean feeling obliged to do something for every patient; it means knowing when to avoid unnecessary treatment. Not every chemotherapy regimen, every combination, or every later-line treatment provides real benefit. Sometimes the right decision is not to add more treatment, but to stop the toxicity. Knowing what to give matters; knowing what not to give matters even more.

#oncology #cancer

[FLoscoMD @fedelosco]

Proud to be part of this incredible panel.
Even prouder to contribute to generating evidence from and for #LATAM.
#ProstateCancer
#Prostatecancer
https://t.co/OaH9y6M05w
@aaoncoclinica @UroTarget @ASCO @LACOG_group

[Kevin Pho, M.D. @kevinmd]

Suicide is now the LEADING cause of death for US medical residents.

We are losing 500 physicians a year. That is an entire med school class. Stop demanding "resilience" from doctors and start fixing the system.

Tie executive bonuses to wellness, not just RVUs.

Link to the recent episode is in the comments 👇

[Prof. Dr. Ahmet Dirican @dr_dirican]

Who is a good oncologist?

A remarkable JCO article attempts to answer this question.

A good oncologist is not merely someone who delivers evidence-based therapy.

🔎 A good oncologist:

• Puts the patient at the center
• Builds trust and meaningful relationships
• Communicates with clarity and compassion
• Possesses emotional intelligence
• Manages the burden of cancer care
• Balances hope with realism
• Commits to lifelong learning and leadership

And my perspective:
A good oncologist is not someone who treats disease strictly according to guidelines,
but someone who never forgets that the person in front of them has emotions, fears, anxieties, and a family — a social life beyond the diagnosis.
Perhaps a good oncologist does not only treat cancer,
but also carries the human being facing it.
@oncodaily #OncoAlert @OncBrothers @myESMO @ASCOPost @JCO_ASCO @JCOOP_ASCO

Good Oncologist: Doctoring Lessons From the Art of Oncology | Journal of Clinical Oncology https://t.co/Eq9m1f4joJ

[Enes Erul MD @ErulEnes]

Imposter Syndrome, Burnout, and Maladaptive Perfectionism Among Oncology Professionals: A Global Cross-Sectional Study | JCO Oncology Practice https://t.co/arjNBBnfk2

Grateful to my mentors,Ankara University, @onkolojidernegi , and proud to serve in the @myESMORTF @DrYukselUrun

[Yakup Ergün @dr_yakupergun]

Being an oncologist is a great profession, but the emotional burden is heavy!

Oncology is the practice of maximizing benefit while balancing toxicity under severe time constraints. Add bureaucratic workload, and you end up ranked third on the list.

https://t.co/Rd8sqR2Pkn

[Yakup Ergün @dr_yakupergun]

ESMO Clinical Practice Guideline Express Update on the adoption of physical exercise in patients with localised colon cancer

https://t.co/QJvrNOKqBX

[David @davidbvcr]

¿Que me rebajen mes a mes parte de mi salario para que a una persona en pobreza le atiendan el parto o le hagan una operación o le den tratamiento oncológico que de otra forma no podría pagar?

Sí. Siempre sí.

[Nico Gagelmann @NicoGagelmann]

Most doctors treat medicine as l'art pour l'art.

But medicine is humanity science: It is much more important to know what sort of patient has a disease than what sort of disease a patient has.

[Young Lung Cancer Initiative @YoungLungCancer]

Theresa was diagnosed at 41 with EGFR lung cancer. After recent progression/LMD- she now uses a wheelchair at times. In this reflection, she shares how it feels to now be seen &amp; treated differently &amp; what keeps her grounded.
🔗 Read the full post: https://t.co/sRXaaicyd3

[David @davidbvcr]

Yo quisiera tener el tiempo y el dinero para poder irme a meter a las zonas marítimo-terrestres de este país y hacer investigaciones y videos sobre lo que estamos permitiendo que suceda con nuestras playas y los terrenos. ¡Es que estamos regalando lo que es nuestro! 😭

[Paolo Tarantino @PTarantinoMD]

What is the cause of ADC-related ILD? Spoiler: most likely not the antibody target (e.g. not HER2). New data confirms prior observations that T-DXd affects alveolar macrophages (AM) via Fc–FcγR engagement, triggering immune activation and ultimately ILD. https://t.co/mxtchICb8W

[Gabriela Arguedas😷💉🧼💦🤲🏼 @gaby_arguedas]

No se qué otra trágica llamada de atención necesita este país para darse cuenta del desaatre en que nos tiene este gobierno.
Sin duda alguna ha elementos que vienen influyendo desde el inicio de la pandemia. Pero estos últimos tres años han sido catastróficos.

[Yüksel Ürün @DrYukselUrun]

BREAKING from @NEJM
In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is :
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection.
#Thrombosis #cancer @OncoAlert @Cihan_Ay_MD
DOI: 10.1056/NEJMoa2416112

[Paolo Tarantino @PTarantinoMD]

The St. Gallen International Breast Cancer Award 2025 goes to Armando E. Giuliano, MD, for his tremendous contribution to axillary management during breast cancer surgery, which led to major reductions in the morbidity of this procedure across the world. #SGBCC2025